Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
Nadofaragene firadenovec is a gene therapy that delivers a copy of a protein called IFNa2b to your kidney. This may help your immune system find and destroy cancer cells. By killing the cancer cells, nadofaragene firadenovec may cause your cancer to stop growing and spreading.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient's white blood cells.
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
Padeliporfin VTP (vascular targeted photodynamic) therapy uses targeted laser light to destroy cancer cells while causing minimal damage to the tissues around the cancer. In this study, researchers want to learn if padeliporfin VTP therapy is effective and safe for people with low-grade upper urothelial cancers (tumors of the kidney or ureter) that have not spread.
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
Bone scans, computed tomography (CT), and magnetic resonance imaging (MRI) are imaging tests used to assess the spread of cancer in the body and to determine whether anticancer treatments are working. Even with these tests, however, it is sometimes difficult to find exactly where the cancer is located and to determine whether it is growing or shrinking in response to treatment. This difficulty is particularly apparent in patients with advanced prostate cancer that has spread to the bones, as standard CT, MRI, as bone scans are not accurate in assessing cancer in the bones.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
